BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Amantadine ER (Gocovri/ADS-5102) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Amantadine ER (Gocovri/ADS-5102)\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07125222-1751@assetmemo.bio
DTSTAMP:20261121T010453Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Amantadine ER (Gocovri/ADS-5102): Phase 2 readout est. (NCT07125222
 )
DESCRIPTION:Amantadine ER (Gocovri/ADS-5102)\, phase 2.\nStudy: Use of Goco
 vri to Improve Disability Due to Radiation Encephalopathy\nEstimated prima
 ry completion: August 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/amantadine-er-gocovri-ads-5102#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07125222
URL:https://assetmemo.bio/drug/amantadine-er-gocovri-ads-5102#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
